# Eloxx Pharmaceuticals, Inc. (ELOX) — capital_raise/public_offering [announced]
Source: SEC API (secapi.ai) · situation sit_ecfc96c703e77c47ee0f · retrieved 2026-08-14T01:26:19.514Z

## Overview
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing exaluren, a small-molecule product candidate designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations, for the treatment of rare kidney diseases including nonsense mutation Alport syndrome and autosomal dominant polycystic kidney disease (ADPKD).

Eloxx Pharmaceuticals, Inc. completed an underwritten public offering of 2,975,000 shares of common stock at $11.00 per share, together with pre-funded warrants to purchase up to 3,025,000 shares of common stock, generating gross proceeds of $66.0 million and net proceeds of approximately $58.3 million after underwriting discounts and commissions. In June 2026, the company completed its uplisting to the Nasdaq Capital Market, where its common stock began trading under the symbol "ELOX."

## Terms
- Deal value: $66.0M · Consideration: stock · Price/share: $11

## Key dates
- Announced 2026-08-11

## Timeline
- 2026-08-11 · 8-K (0001193125-26-345032): 8-K - Eloxx Pharmaceuticals, Inc. — *Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing exaluren, a small-molecule product candidate designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations, for the treatment of rare kidney diseases including nonsense mutation Alport syndrome and autosomal dominant polycystic kidney disease (ADPKD).* Eloxx Pharmaceuticals, Inc. completed an underwritten public offering of 2,975,000 shares of common stock at $11.00 per share, together with pre-funded warrants to purchase up to 3,025,000 shares of common stock, generating gross proceeds of $66.0 million and net proceeds of approximately $58.3 million after underwriting discounts and commissions. In June 2026, the company completed its uplisting to the Nasdaq Capital Market, where its common stock began trading under the symbol "ELOX."
  https://www.sec.gov/Archives/edgar/data/1035354/0001193125-26-345032.txt

## Citations
- 0001193125-26-345032 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526345032